COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Impact of Lymphocyte Anti-metabolite Immunosuppressions on Donor-Specific Anti-HLA Antibody and Kidney Graft Outcome

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03794492
Recruitment Status : Active, not recruiting
First Posted : January 7, 2019
Last Update Posted : February 18, 2020
Information provided by (Responsible Party):
Chong Kun Dang Pharmaceutical

Brief Summary:
Efficacy and Safety of My-Rept® (Mycophenolate Mofetil 500mg/Tab. or 250mg/Cap.) in Combination with Tacrolimus, Methylprednisolone, Simulect in Kidney Transplant Patients

Condition or disease Intervention/treatment Phase
Kidney Transplant Patients Drug: Mycophenolate Mofetil 500Mg Tab. or 250Mg Cap. Drug: Tacrolimus Drug: Methylprednisolone/prednisone Drug: Simulect® (Basiliximab) Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 158 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Impact of Lymphocyte Anti-metabolite Immunosuppressions on Donor-Specific Anti-HLA Antibody and Kidney Graft Outcome: Open-label, Multi-center, Single Arm, Phase 4 Trial (DoSAKOM)
Actual Study Start Date : March 31, 2018
Estimated Primary Completion Date : March 21, 2022
Estimated Study Completion Date : November 29, 2022

Arm Intervention/treatment
Experimental: Mycophenolate Mofetil 500Mg Tab. or 250Mg Cap.
Mycophenolate Mofetil 500Mg Tab. or 250Mg Cap.
Drug: Mycophenolate Mofetil 500Mg Tab. or 250Mg Cap.
Mycophenolate mofetil 1,000 ~ 2,000mg
Other Name: Mycophenolate mofetil 1,000 ~ 2,000mg

Drug: Tacrolimus

Drug: Methylprednisolone/prednisone

Drug: Simulect® (Basiliximab)
Simulect® (Basiliximab)

Primary Outcome Measures :
  1. DSA(Donor-specific Anti-HLA Antibody) [ Time Frame: 36 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   19 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  1. Over 20 years old(male or female)
  2. Patients who are planning to receive a kidney from a deceased or a living non-related/related donor
  3. Agreement with written informed consent

Exclusion Criteria:

  1. Patient who receive a kidney from a related donor who showed HLA-0 mismatch (identical)
  2. Undergo desensitization therapy with high sensitization
  3. Patient with dual kidney transplantation recipient or have history of other organ transplantation in past or current.
  4. Patient who receive extra-renal solid organ or bone marrow stem cell transplantation.
  5. Patient who receive kidney transplantation from non-heart beating cadaveric donor(organ donor after cardiac death
  6. Patient who receive kidney transplantation from ABO blood type mismatching donor or lymphocyte cross matching (LCM) positive donor.
  7. Patient with cancer within 5 years, except cured skin cancer patient(Squamous cell or basal cell carcinoma or Early stage Renal cell carcinoma or Thyroid Cancer)
  8. Positive in serology test(HIV, HBsAg, HCV) in recipients and/or donor.
  9. Defined by the following laboratory parameters before screening period

    • Treatment with active liver disease or Liver function test(T-bilirubin, AST, ALT, ALP)is over 3 times than upper normal limit
    • ANC < 1,500/mm^3, or WBC < 2,500/mm^3, or Platelet < 50,000/mm^3
  10. Acute (within 4 weeks) or chronic(need to treatments) allergic/hypersensitivity reaction in the history of Investigational drugs (ex, mycophenolate acid or tacrolimus, etc.) or additives.
  11. Administration of other Investigational drugs and/or immunosuppressants within 30days before screening period (except allowed immunosuppressants in protocol)
  12. Women in pregnant or breast-feeding or don't using adequate contraception.
  13. Patient has conversation impairment because alcohol or drugs addiction history within 6months or mental illness, etc.
  14. In investigator's judgment

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03794492

Layout table for location information
Korea, Republic of
Ajou University Hospital
Suwan, Korea, Republic of
Sponsors and Collaborators
Chong Kun Dang Pharmaceutical
Layout table for investigator information
Study Chair: Chang-Kwan Oh, Ph.D Ajou University School of Medicine
Layout table for additonal information
Responsible Party: Chong Kun Dang Pharmaceutical Identifier: NCT03794492    
Other Study ID Numbers: 223KT17017
First Posted: January 7, 2019    Key Record Dates
Last Update Posted: February 18, 2020
Last Verified: February 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Mycophenolic Acid
Anti-Inflammatory Agents
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Antineoplastic Agents, Hormonal
Antineoplastic Agents
Immunosuppressive Agents
Immunologic Factors
Calcineurin Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antibiotics, Antineoplastic
Antibiotics, Antitubercular
Antitubercular Agents
Anti-Bacterial Agents
Anti-Infective Agents
Autonomic Agents
Peripheral Nervous System Agents
Gastrointestinal Agents
Neuroprotective Agents
Protective Agents